id stringlengths 24 24 | type stringclasses 1
value | question stringlengths 13 210 | answer listlengths 1 1 | ideal_answer listlengths 1 70 | documents listlengths 1 133 | snippets listlengths 1 114 | asq_challenge int32 1 13 | split_13b stringclasses 2
values |
|---|---|---|---|---|---|---|---|---|
56bc751eac7ad10019000013 | factoid | Name synonym of Acrokeratosis paraneoplastica. | [
[
"Bazex syndrome"
]
] | [
"Acrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/3819049",
"http://www.ncbi.nlm.nih.gov/pubmed/18775590",
"http://www.ncbi.nlm.nih.gov/pubmed/22146896",
"http://www.ncbi.nlm.nih.gov/pubmed/6225397",
"http://www.ncbi.nlm.nih.gov/pubmed/18672707",
"http://www.ncbi.nlm.nih.gov/pubmed/7796616",
"http://www.ncbi.nlm.nih.... | [
{
"text": "Acrokeratosis paraneoplastica of Bazex is a rare but important paraneoplastic dermatosis, usually manifesting as psoriasiform rashes over the acral sites.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/22252191",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginS... | 4 | train |
56c1f01def6e394741000045 | factoid | Orteronel was developed for treatment of which cancer? | [
[
"castration-resistant prostate cancer"
]
] | [
"Orteronel was developed for treatment of castration-resistant prostate cancer."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24799061",
"http://www.ncbi.nlm.nih.gov/pubmed/24418642",
"http://www.ncbi.nlm.nih.gov/pubmed/25537627",
"http://www.ncbi.nlm.nih.gov/pubmed/25701170",
"http://www.ncbi.nlm.nih.gov/pubmed/25624429",
"http://www.ncbi.nlm.nih.gov/pubmed/25264242",
"http://www.ncbi.nlm.n... | [
{
"text": "Pooled-analysis was also performed, to assess the effectiveness of agents targeting the androgen axis via identical mechanisms of action (abiraterone acetate, orteronel).",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028",
"beginSection": "abstract",
"endSection": "abstract",
... | 4 | train |
56af9f130a360a5e45000015 | factoid | Where is the protein Pannexin1 located? | [
[
"plasma membrane"
]
] | [
"The protein Pannexin1 is localized to the plasma membranes."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24642372",
"http://www.ncbi.nlm.nih.gov/pubmed/25056878",
"http://www.ncbi.nlm.nih.gov/pubmed/24694658",
"http://www.ncbi.nlm.nih.gov/pubmed/25698922",
"http://www.ncbi.nlm.nih.gov/pubmed/17064878",
"http://www.ncbi.nlm.nih.gov/pubmed/24782784",
"http://www.ncbi.nlm.n... | [
{
"text": "zfPanx1 was identified on the surface of horizontal cell dendrites invaginating deeply into the cone pedicle near the glutamate release sites of the cones, providing in vivo evidence for hemichannel formation at that location.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/19409451",
"begi... | 4 | train |
52bf1b0a03868f1b06000009 | factoid | What is the mode of inheritance of Wilson's disease? | [
[
"autosomal recessive"
]
] | [
"Wilson's disease (WD) is an autosomal recessive disorder."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/838566",
"http://www.ncbi.nlm.nih.gov/pubmed/8615372",
"http://www.ncbi.nlm.nih.gov/pubmed/12152840",
"http://www.ncbi.nlm.nih.gov/pubmed/1940586",
"http://www.ncbi.nlm.nih.gov/pubmed/6109943",
"http://www.ncbi.nlm.nih.gov/pubmed/1248830",
"http://www.ncbi.nlm.nih.gov... | [
{
"text": "The disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/16932613",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSecti... | 2 | train |
52bf19c503868f1b06000001 | factoid | What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)? | [
[
"autosomal dominant"
]
] | [
"Facioscapulohumeral muscular dystrophy has an autosomal dominant inheritance pattern."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/10487912",
"http://www.ncbi.nlm.nih.gov/pubmed/15307599",
"http://www.ncbi.nlm.nih.gov/pubmed/10969520",
"http://www.ncbi.nlm.nih.gov/pubmed/19248726",
"http://www.ncbi.nlm.nih.gov/pubmed/10864616",
"http://www.ncbi.nlm.nih.gov/pubmed/23143600",
"http://www.ncbi.nlm.n... | [
{
"text": "autosomal dominant FSHD1",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 214,
"offsetInEndSection": 238
},
{
"text": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular... | 2 | train |
5505edac8e1671127b000005 | factoid | What kind of chromatography is HILIC? | [
[
"Hydrophilic Interaction Chromatography"
]
] | [
"Hydrophilic Interaction Chromatography (HILIC)"
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/21737084",
"http://www.ncbi.nlm.nih.gov/pubmed/23217321",
"http://www.ncbi.nlm.nih.gov/pubmed/22946920",
"http://www.ncbi.nlm.nih.gov/pubmed/23073287",
"http://www.ncbi.nlm.nih.gov/pubmed/21238772",
"http://www.ncbi.nlm.nih.gov/pubmed/21316059"
] | [
{
"text": "hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23217321",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 2,
"offsetInEndSection": 96
},
{
"text"... | 3 | train |
56e2cec751531f7e33000015 | factoid | What is the structural fold of bromodomain proteins? | [
[
"All-alpha-helical fold"
]
] | [
"The structure fold of the bromodomains is an all-alpha-helical fold, which includes a left-handed four-helix bundle topology, with two short additional helices in a long connecting loop."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/17498659",
"http://www.ncbi.nlm.nih.gov/pubmed/17148447",
"http://www.ncbi.nlm.nih.gov/pubmed/17694091",
"http://www.ncbi.nlm.nih.gov/pubmed/10827952",
"http://www.ncbi.nlm.nih.gov/pubmed/17848202",
"http://www.ncbi.nlm.nih.gov/pubmed/17582821",
"http://www.ncbi.nlm.n... | [
{
"text": "These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.",
"document": "http://www.ncbi.nlm.nih.gov/pubme... | 4 | train |
5518e7da622b194345000004 | factoid | Which MAP kinase phosphorylates the transcription factor c-jun? | [
[
"c-Jun NH2-terminal kinase",
"JNK"
]
] | [
"c-Jun is phosphorylated by c-Jun NH2-terminal kinase (JNK).",
"An in vitro kinase assay revealed that c-Jun phosphorylation is primarily mediated via activated c-Jun N-terminal protein kinase (JNK)."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24113186",
"http://www.ncbi.nlm.nih.gov/pubmed/24300195",
"http://www.ncbi.nlm.nih.gov/pubmed/24272171",
"http://www.ncbi.nlm.nih.gov/pubmed/24291243",
"http://www.ncbi.nlm.nih.gov/pubmed/24252081",
"http://www.ncbi.nlm.nih.gov/pubmed/15228586",
"http://www.ncbi.nlm.n... | [
{
"text": " c-Jun NH2-terminal kinase (JNK)",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24321566",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 955,
"offsetInEndSection": 987
},
{
"text": " c-jun N-terminal kinase (JNK) of mitogen-activated prot... | 3 | train |
530a5117970c65fa6b000007 | factoid | What is the meaning of the acronym "TAILS" used in protein N-terminomics? | [
[
"TAILS: Terminal Amine Isotopic Labeling of Substrates"
]
] | [
"TAILS stands for \"Terminal Amine Isotopic Labeling of Substrates\""
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/20305284",
"http://www.ncbi.nlm.nih.gov/pubmed/21604127",
"http://www.ncbi.nlm.nih.gov/pubmed/22577022",
"http://www.ncbi.nlm.nih.gov/pubmed/21604129",
"http://www.ncbi.nlm.nih.gov/pubmed/23667905",
"http://www.ncbi.nlm.nih.gov/pubmed/22367194"
] | [
{
"text": ". It is important to identify what proteins are substrates of proteases and where their cleavage sites are so as to reveal the molecular mechanisms and specificity of signaling. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/21604127",
"beginSection": "abstract",
"endSection": "abstra... | 2 | train |
552fac4fbc4f83e828000006 | factoid | Which fusion protein is involved in the development of Ewing sarcoma? | [
[
"EWS/FLI1"
]
] | [
"Ewing sarcoma is the second most common bone malignancy in children and young adults. In almost 95% of the cases, it is driven by oncogenic fusion protein EWS/FLI1, which acts as an aberrant transcription factor, that upregulates or downregulates target genes, leading to cellular transformation."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/25432018",
"http://www.ncbi.nlm.nih.gov/pubmed/21979944",
"http://www.ncbi.nlm.nih.gov/pubmed/16206264",
"http://www.ncbi.nlm.nih.gov/pubmed/18256529",
"http://www.ncbi.nlm.nih.gov/pubmed/25162919",
"http://www.ncbi.nlm.nih.gov/pubmed/19718047",
"http://www.ncbi.nlm.n... | [
{
"text": "Ewing sarcoma is the second most common bone malignancy in children and young adults. It is driven by oncogenic fusion proteins (i.e. EWS/FLI1) acting as aberrant transcription factors that upregulate and downregulate target genes, leading to cellular transformation",
"document": "http://www.ncbi... | 3 | train |
54cf7051f693c3b16b000013 | factoid | Treatment of which disease was investigated in the MR CLEAN study? | [
[
"acute ischemic stroke"
]
] | [
"Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) study investigated endovascular treatment for acute ischemic stroke."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/25517348",
"http://www.ncbi.nlm.nih.gov/pubmed/25432979",
"http://www.ncbi.nlm.nih.gov/pubmed/25179366",
"http://www.ncbi.nlm.nih.gov/pubmed/24330796"
] | [
{
"text": "INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS)... | 3 | train |
54e0d1491388e8454a000014 | factoid | Which enzyme is targeted by Evolocumab? | [
[
"proprotein convertase subtilisin/kexin type 9"
]
] | [
"Evolocumab (AMG145) is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that demonstrated marked reductions in plasma low-density lipoprotein cholesterol concentrations in statin-intolerant patients."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24691094",
"http://www.ncbi.nlm.nih.gov/pubmed/25410046",
"http://www.ncbi.nlm.nih.gov/pubmed/25052769",
"http://www.ncbi.nlm.nih.gov/pubmed/24661068",
"http://www.ncbi.nlm.nih.gov/pubmed/24477778",
"http://www.ncbi.nlm.nih.gov/pubmed/25079474",
"http://www.ncbi.nlm.n... | [
{
"text": "Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24661068",
"beginSection": "title",
"endSection": "title",
"offsetInBegi... | 3 | train |
51404dd723fec90375000002 | factoid | What is the methyl donor of DNA (cytosine-5)-methyltransferases? | [
[
"S-adenosyl-L-methionine"
]
] | [
"S-adenosyl-L-methionine (AdoMet, SAM) is the methyl donor of DNA (cytosine-5)-methyltransferases. DNA (cytosine-5)-methyltransferases catalyze the transfer of a methyl group from S-adenosyl-L-methionine to the C-5 position of cytosine residues in DNA."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/7578083",
"http://www.ncbi.nlm.nih.gov/pubmed/8441638",
"http://www.ncbi.nlm.nih.gov/pubmed/1584813",
"http://www.ncbi.nlm.nih.gov/pubmed/11208790",
"http://www.ncbi.nlm.nih.gov/pubmed/8065896",
"http://www.ncbi.nlm.nih.gov/pubmed/15273274",
"http://www.ncbi.nlm.nih.g... | [
{
"text": "The product of the dcm gene is the only DNA cytosine-C5 methyltransferase of Escherichia coli K-12; it catalyses transfer of a methyl group from S-adenosyl methionine (SAM) to the C-5 position of the inner cytosine residue of the cognate sequence CCA/TGG. ",
"document": "http://www.ncbi.nlm.nih.g... | 1 | train |
56d0451c3975bb303a00000e | factoid | Which signaling pathway does sonidegib inhibit? | [
[
"Hedghog signalling pathway"
]
] | [
"Sonidegib is a Hedghog signalling pathway inhibitor."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24598114",
"http://www.ncbi.nlm.nih.gov/pubmed/25981810",
"http://www.ncbi.nlm.nih.gov/pubmed/24523439",
"http://www.ncbi.nlm.nih.gov/pubmed/24613036",
"http://www.ncbi.nlm.nih.gov/pubmed/25646180",
"http://www.ncbi.nlm.nih.gov/pubmed/24817600",
"http://www.ncbi.nlm.n... | [
{
"text": "The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/25473003",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 942,
"offsetInEnd... | 4 | train |
54ede8c594afd61504000009 | factoid | In which phase of the cell cycle arrest is impaired in Fanconi anemia? | [
[
"In Fanconi anemia cells, the S-phase checkpoint is inefficient."
]
] | [
"In response to damage induced by DNA cross-linking agents, the S-phase checkpoint is inefficient in Fanconi anemia (FA) cells, leading to accumulation of secondary lesions, such as single- and double-strand breaks and gaps. The prolonged time in G2 phase seen in FA cells therefore exists in order to allow the cell... | [
"http://www.ncbi.nlm.nih.gov/pubmed/11035915",
"http://www.ncbi.nlm.nih.gov/pubmed/9414295",
"http://www.ncbi.nlm.nih.gov/pubmed/14988723",
"http://www.ncbi.nlm.nih.gov/pubmed/9650445",
"http://www.ncbi.nlm.nih.gov/pubmed/11749045"
] | [
{
"text": "We found that ICLs activate a branched pathway downstream of the ATR kinase: one branch depending on CHK1 activity and the other on the FANCs-RMN complex. The transient slow-down of DNA synthesis was abolished in cells lacking ATR, whereas CHK1-siRNA-treated cells, NBS1 or FA cells showed partial S-p... | 3 | train |
551c23bc6b348bb82c00000b | factoid | Mutation of which gene is implicated in the familial isolated pituitary adenoma? | [
[
"aryl hydrocarbon receptor interacting protein"
]
] | [
"Mutation of aryl hydrocarbon receptor interacting protein (AIP) gene was implicated in the familial isolated pituitary adenoma (FIPA) syndrome. About 20% of the families with FIPA harbor inactivating mutation in AIP gene."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/23743763",
"http://www.ncbi.nlm.nih.gov/pubmed/24078436",
"http://www.ncbi.nlm.nih.gov/pubmed/24050928",
"http://www.ncbi.nlm.nih.gov/pubmed/20457215",
"http://www.ncbi.nlm.nih.gov/pubmed/22915287",
"http://www.ncbi.nlm.nih.gov/pubmed/17961654",
"http://www.ncbi.nlm.n... | [
{
"text": "The cause of familial isolated pituitary adenomas (FIPA) remains unknown in a high percentage of cases, but the AIP gene plays an important role in the etiology. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436",
"beginSection": "abstract",
"endSection": "abstract",
"offset... | 3 | train |
56c1f02cef6e39474100004c | factoid | GV1001 vaccine targets which enzyme? | [
[
"human telomerase reverse transcriptase"
]
] | [
"GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. It has been developed as a vaccine against various cancers."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/24815142",
"http://www.ncbi.nlm.nih.gov/pubmed/19072345",
"http://www.ncbi.nlm.nih.gov/pubmed/24954781",
"http://www.ncbi.nlm.nih.gov/pubmed/21377838",
"http://www.ncbi.nlm.nih.gov/pubmed/19388882",
"http://www.ncbi.nlm.nih.gov/pubmed/23827187",
"http://www.ncbi.nlm.n... | [
{
"text": "A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24411674",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 0,
"o... | 4 | train |
550af222c2af5d5b7000000b | factoid | Which is the E3 ubiquitin ligase which ubiquitinates IkB leading to its proteasomal degradation? | [
[
"SCF(β-TrCP)",
"SCF beta-transducin repeat-containing protein (beta-TrCP)",
"beta-Trcp"
]
] | [
"IκB degradation involves ubiquitination mediated by a specific E3 ubiquitin ligase SCF(β-TrCP). SCF(β-TrCP) -mediated IκB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor IκBα within a few minutes of cell stimulation.",
"IkappaB degradation ... | [
"http://www.ncbi.nlm.nih.gov/pubmed/22435548",
"http://www.ncbi.nlm.nih.gov/pubmed/17001349",
"http://www.ncbi.nlm.nih.gov/pubmed/16778892",
"http://www.ncbi.nlm.nih.gov/pubmed/10837071",
"http://www.ncbi.nlm.nih.gov/pubmed/20028970"
] | [
{
"text": "IKK activation and IκB degradation involve different ubiquitination modes; the latter is mediated by a specific E3 ubiquitin ligase SCF(β-TrCP) . The F-box component of this E3, β-TrCP, recognizes the IκB degron formed following phosphorylation by IKK and thus couples IκB phosphorylation to ubiquitin... | 3 | train |
56c1f03bef6e394741000053 | factoid | Mutation of which gene is implicated in the Brain-lung-thyroid syndrome? | [
[
"thyroid transcription factor 1"
]
] | [
"Brain-lung-thyroid syndrome (BLTS) characterized by congenital hypothyroidism, respiratory distress syndrome, and benign hereditary chorea is caused by thyroid transcription factor 1 (NKX2-1/TTF1) mutations."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/22166853",
"http://www.ncbi.nlm.nih.gov/pubmed/20020530",
"http://www.ncbi.nlm.nih.gov/pubmed/25759798",
"http://www.ncbi.nlm.nih.gov/pubmed/26196025",
"http://www.ncbi.nlm.nih.gov/pubmed/24129101",
"http://www.ncbi.nlm.nih.gov/pubmed/22488412",
"http://www.ncbi.nlm.n... | [
{
"text": " The disorder is caused by mutations to the NKX2.1 (TITF1) gene and also forms part of the \"brain-lung-thyroid syndrome\", in which additional developmental abnormalities of lung and thyroid tissue are observed. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26196025",
"beginSection": "a... | 4 | train |
532498959b2d7acc7e000017 | factoid | Which enzyme is targeted by the drug Imetelstat? | [
[
"Human Telomerase"
]
] | [
"Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA subunit. In preclinical trials, this compound has been found to inhibit telomer... | [
"http://www.ncbi.nlm.nih.gov/pubmed/21208905",
"http://www.ncbi.nlm.nih.gov/pubmed/23386830",
"http://www.ncbi.nlm.nih.gov/pubmed/21549308",
"http://www.ncbi.nlm.nih.gov/pubmed/23521791",
"http://www.ncbi.nlm.nih.gov/pubmed/23558965",
"http://www.ncbi.nlm.nih.gov/pubmed/23545855",
"http://www.ncbi.nlm.n... | [
{
"text": "Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
"beginSection": "title",
"endSection": "title",
"offsetInBeginSection": 0,
"offsetInEndSection": 83
},
{
"text": "imetelstat sod... | 2 | train |
56d06e043975bb303a000011 | factoid | In which breast cancer patients can palbociclib be used? | [
[
"hormone receptor-positive, human epidermal growth factor receptor 2-negative"
]
] | [
"Palbociclib is useful for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/25524798",
"http://www.ncbi.nlm.nih.gov/pubmed/25792301",
"http://www.ncbi.nlm.nih.gov/pubmed/26236140"
] | [
{
"text": "Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/26236140",
"beginSection": "abstract",
"endSection": "... | 4 | train |
5509f433c2af5d5b70000008 | factoid | What is the method FASP used for? | [
[
"proteomic sample preparation"
]
] | [
"Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/23603217",
"http://www.ncbi.nlm.nih.gov/pubmed/22949036",
"http://www.ncbi.nlm.nih.gov/pubmed/24051509",
"http://www.ncbi.nlm.nih.gov/pubmed/24022122",
"http://www.ncbi.nlm.nih.gov/pubmed/24288579",
"http://www.ncbi.nlm.nih.gov/pubmed/22324799",
"http://www.ncbi.nlm.n... | [
{
"text": "FASP (filter-aided sample preparation) ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/24309553",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 197,
"offsetInEndSection": 236
},
{
"text": "mouse brain tissue lysate was prepared using filt... | 3 | train |
531a34d5b166e2b806000036 | factoid | Which gene is required for the efficient function of clopidogrel? | [
[
"cytochrome P450, CYPC19"
]
] | [
"The prodrug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 CYP2C19), transport proteins (P-glycoprotein) and/or target proteins for t... | [
"http://www.ncbi.nlm.nih.gov/pubmed/23150151",
"http://www.ncbi.nlm.nih.gov/pubmed/21806387",
"http://www.ncbi.nlm.nih.gov/pubmed/15933261",
"http://www.ncbi.nlm.nih.gov/pubmed/21099121",
"http://www.ncbi.nlm.nih.gov/pubmed/19463375",
"http://www.ncbi.nlm.nih.gov/pubmed/20826260",
"http://www.ncbi.nlm.n... | [
{
"text": "The CYP2C19 G681A single polymorphism has been proven to affect clopidogrel responsiveness. ",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23506580",
"beginSection": "abstract",
"endSection": "abstract",
"offsetInBeginSection": 12,
"offsetInEndSection": 104
},
{
"text"... | 2 | train |
56cdf40d5795f9a73e00003d | factoid | Which transcription factor is considered as a master regulator of lysosomal genes? | [
[
"Transcription factor EB (TFEB)"
]
] | [
"Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and autophagy, driving lysosome adaptation to environmental cues, such as starvation, and therefore targeting of TFEB may provide a novel therapeutic strategy for modulating lysosomal function in human disease."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/22343943",
"http://www.ncbi.nlm.nih.gov/pubmed/23457305",
"http://www.ncbi.nlm.nih.gov/pubmed/25315655",
"http://www.ncbi.nlm.nih.gov/pubmed/23401004",
"http://www.ncbi.nlm.nih.gov/pubmed/25750174",
"http://www.ncbi.nlm.nih.gov/pubmed/23830905",
"http://www.ncbi.nlm.n... | [
{
"text": "In this paper, we identify a novel role for Rags in controlling activation of transcription factor EB (TFEB), a master regulator of autophagic and lysosomal gene expression",
"document": "http://www.ncbi.nlm.nih.gov/pubmed/23401004",
"beginSection": "abstract",
"endSection": "abstract",
... | 4 | train |
553653a5bc4f83e828000007 | factoid | Which technique is used for detection of EWS/FLI1 fusion transcripts? | [
[
"Reverse transcription - polymerase chain reaction (RT-PCR)"
]
] | [
"Molecular detection of EWS-FLI1 chimeric transcripts in Ewing family tumors is carried out by reverse transcription-polymerase chain reaction (RT-PCR)."
] | [
"http://www.ncbi.nlm.nih.gov/pubmed/23475435",
"http://www.ncbi.nlm.nih.gov/pubmed/20231617",
"http://www.ncbi.nlm.nih.gov/pubmed/9552022",
"http://www.ncbi.nlm.nih.gov/pubmed/16157025",
"http://www.ncbi.nlm.nih.gov/pubmed/10379685",
"http://www.ncbi.nlm.nih.gov/pubmed/24293381",
"http://www.ncbi.nlm.ni... | [
{
"text": "We evaluated the feasibility and usefulness of reverse transcriptase-polymerase chain reaction (RT-PCR) on fine-needle aspirates for categorization of small blue round cell tumors (SBRCTs). A total of 51 cases, including 25 Ewing sarcoma/peripheral primitive neuroectodermal tumors (PNETs), 11 rhabdom... | 3 | train |
BioASQ 14B — Biomedical Question Answering
The complete training corpus for BioASQ Task 14B, repackaged as a HuggingFace dataset. 5,729 expert-annotated biomedical questions, each with relevant PubMed documents, extracted snippets, an exact answer and several reference long-form answers.
This is a faithful repackaging of training14b.json — no questions were added, removed
or reworded. Two columns were derived to make the challenge history usable
(asq_challenge and split_13b), and exact_answer was normalized into a single
consistent shape.
Splits
The dataset is split by question type rather than by train/test, because all 5,729 questions are 14B training data. Choose your own evaluation split - see below.
| Split | Questions |
|---|---|
factoid |
1,695 |
list |
1,130 |
summary |
1,363 |
yesno |
1,541 |
| total | 5,729 |
Columns
| Column | Type | Description |
|---|---|---|
id |
string |
Official BioASQ question id, stable across challenge editions |
type |
string |
factoid, list, summary or yesno (same as the split name) |
question |
string |
The question text |
answer |
list[list[string]] |
Exact answer. Outer list holds distinct answer items, inner list holds accepted synonyms. Empty for summary. |
ideal_answer |
list[string] |
Reference long-form answers, several per question |
documents |
list[string] |
PubMed URLs of the relevant articles |
snippets |
list[struct] |
Relevant text spans, with text, document, beginSection, endSection, offsetInBeginSection, offsetInEndSection |
asq_challenge |
int32 |
Challenge edition (1–13) in which the question was first introduced |
split_13b |
string |
train or test — which side of the BioASQ 13 challenge split this question fell on |
The answer column
BioASQ stores exact_answer in three different shapes depending on question type. This
dataset normalizes all of them to list[list[string]] so the column has one Arrow type:
| Type | Original | Normalized |
|---|---|---|
yesno |
"yes" |
[["yes"]] |
factoid |
["Bazex syndrome"] |
[["Bazex syndrome"]] |
list |
[["epidermal growth factor"], ["betacellulin"]] |
unchanged |
summary |
absent | [] |
For yesno, read row["answer"][0][0]. For factoid, row["answer"][0] is the list of
accepted synonyms. For list, each element of row["answer"] is one required list item
with its synonyms.
The asq_challenge column
The edition in which a question first appeared, computed by scanning every training
release (2b–14b) and every golden test set (Task2B–Task13B), plus the BioASQ 1
task1b phase testsets that ship inside the BioASQ-training2b folder. The 301
questions marked edition 1 are the original BioASQ 1 questions.
| Edition | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Questions | 301 | 460 | 494 | 492 | 498 | 499 | 499 | 499 | 492 | 485 | 330 | 340 | 340 |
Useful for time-based splits: training on asq_challenge <= 11 and evaluating on
asq_challenge >= 12 reproduces a realistic temporal generalization setup. For the latest available train/test split (as of 16.09.2026 this is version 13b) you can also use feature split_13b.
The 13b_split column
BioASQ folds each year's golden test questions into the following year's training
release, so training14b.json is exactly training13b.json (5,389 questions) plus the
340 questions used as the BioASQ 13 test set. This column records that boundary, letting
you reproduce the official 13B split without downloading the golden test files.
Usage
from datasets import load_dataset, concatenate_datasets
ds = load_dataset("JJBauer/bioasq-14b")
# One question type
factoid = ds["factoid"]
# Everything at once
everything = concatenate_datasets([ds[t] for t in ["factoid", "list", "summary", "yesno"]])
Reproduce the official BioASQ 13 split:
train = everything.filter(lambda r: r["13b_split"] == "train") # 5,389
test = everything.filter(lambda r: r["13b_split"] == "test") # 340
A temporal split by challenge edition:
train = everything.filter(lambda r: r["asq_challenge"] <= 11)
test = everything.filter(lambda r: r["asq_challenge"] >= 12)
A note on evaluation
Because BioASQ absorbs old test sets into new training releases, the published golden
test sets for editions 2–13 are almost entirely contained in this corpus: of 5,486
pooled test questions, 5,483 (99.9%) are present here. Do not evaluate on downloaded
TaskNBGoldenEnriched files while training on this dataset — use 13b_split or
asq_challenge to carve out a holdout instead, or evaluate against the BioASQ 14 test
sets, which are not part of this corpus by construction.
Citation
If you use this dataset, you must cite the original BioASQ papers (the first two below).
@article{krithara2023bioasq,
title = {BioASQ-QA: A manually curated corpus for Biomedical Question Answering},
author = {Krithara, Anastasia and Nentidis, Anastasios and Bougiatiotis, Konstantinos and Paliouras, Georgios},
journal = {Scientific Data},
volume = {10},
pages = {170},
year = {2023},
publisher = {Nature Publishing Group UK London}
}
@article{tsatsaronis2015overview,
title={An overview of the BIOASQ large-scale biomedical semantic indexing and question answering competition},
author={Tsatsaronis, George and Balikas, Georgios and Malakasiotis, Prodromos and Partalas, Ioannis and Zschunke, Matthias and Alvers, Michael R and Weissenborn, Dirk and Krithara, Anastasia and Petridis, Sergios and Polychronopoulos, Dimitris and others},
journal={BMC bioinformatics},
volume={16},
number={1},
pages={138},
year={2015},
publisher={Springer}
}
Licensing
The BioASQ data is distributed by the BioASQ organisers; consult bioasq.org and the participants area for the terms that apply to the original corpus. This repackaging does not change those terms.
- Downloads last month
- 215